Abstract:Background Heterogeneity of leukemia-initiating cells (LICs) is a major obstacle in acute myeloid leukemia (AML) therapy. Accumulated evidence indicates that the coexistence of multiple types of LICs with different pathogenicity in the same individual is a common feature in AML. However, the functional heterogeneity including the drug response of coexistent LICs remains unclear. Therefore, this study aimed to clarify the intra-heterogeneity in LICs that can help predict leukemia behavior and develop more effective treatments. Methods Spleen cells from the primary Setd2(-/-)-AML mouse were transplanted into C57BL/6 recipient mice to generate a transplantable model. Flow cytometry was used to analyze the immunophenotype of the leukemic mice. Whole-genome sequencing was conducted to detect secondary hits responsible for leukemia transformation. A serial transplantation assay was used to determine the self-renewal potential of Setd2(-/-)-AML cells. A limiting-dilution assay was performed to identify the LIC frequency in different subsets of leukemia cells. Bulk and single-cell RNA sequencing were performed to analyze the transcriptional heterogeneity of LICs. Small molecular inhibitor screening and in vivo drug treatment were employed to clarify the difference in drug response between the different subsets of LICs. Results In this study, we observed an aged Setd2(-/-) mouse developing AML with co-mutation of Nras(G12S) and Braf(K520E). Further investigation identified two types of LICs residing in the c-Kit(+)B220(+)Mac-1(-) and c-Kit(+)B220(+)Mac-1(+) subsets, respectively. In vivo transplantation assay disclosed the heterogeneity in differentiation between the coexistent LICs. Besides, an intrinsic doxorubicin-resistant transcriptional signature was uncovered in c-Kit(+)B220(+)Mac-1(+) cells. Indeed, doxorubicin plus cytarabine (DA), the standard chemotherapeutic regimen used in AML treatment, could specifically kill c-Kit(+)B220(+)Mac-1(-) cells, but it hardly affected c-Kit(+)B220(+)Mac-1(+) cells. Transcriptome analysis unveiled a higher activation of RAS downstream signaling pathways in c-Kit(+)B220(+)Mac-1(+) cells than in c-Kit(+)B220(+)Mac-1(-) cells. Combined treatment with DA and RAS pathway inhibitors killed both c-Kit(+)B220(+)Mac-1(-) and c-Kit(+)B220(+)Mac-1(+) cells and attenuated disease progression. Conclusions This study identified two cell subsets enriched for LICs in murine Setd2(-/-)-AML and disclosed the transcriptional and functional heterogeneity of LICs, revealing that the coexistence of different types of LICs in this model brings about diverse drug response.

Lics of Apl-Like Leukemia Lead A Step-Wise and Divergent Differentiation Course

Single-cell multiomics reveals a gene regulatory circuit promoting leukemia cell differentiation

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Intra‐heterogeneity in Transcription and Chemoresistant Property of Leukemia‐initiating Cells in Murine Setd2−/− Acute Myeloid Leukemia

Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity

Disruption of Dntp Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease

Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia

Distinct Leukemia Phenotypes in Transgenic Mice and Different Corepressor Interactions Generated by Promyelocytic Leukemia Variant Fusion Genes PLZF–RAR Α and NPM–RAR Α

From Molecular Interaction to Acute Promyelocytic Leukemia: Calculating Leukemogenesis and Remission from Endogenous Molecular-Cellular Network

Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia

Induced Lineage Promiscuity Undermines the Efficiency of All-Trans-retinoid-acid-induced Differentiation of Acute Myeloid Leukemia

Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins

Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia

JAM3 Maintains Leukemia-Initiating Cell Self-Renewal Through LRP5/AKT/β-catenin/CCND1 Signaling

A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells

Transcriptional Repression of CDKN2D by PML/RARα Contributes to the Altered Proliferation and Differentiation Block of Acute Promyelocytic Leukemia Cells

Reinforced Erythroid Differentiation Inhibits Leukemogenic Potential of T(8;21) Leukemia

New Insight of Leukemic Stem Cell